Tonix Pharmaceuticals (TNXP) & Its Rivals Head-To-Head Review

Tonix Pharmaceuticals (NASDAQ:TNXP) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Tonix Pharmaceuticals to similar businesses based on the strength of its institutional ownership, profitability, valuation, risk, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Tonix Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals’ competitors have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Tonix Pharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1	0	1	2	3.00
Tonix Pharmaceuticals Competitors	9846	15129	45496	1589	2.54

Tonix Pharmaceuticals currently has a consensus price target of $22.33, suggesting a potential upside of 397.40%. As a group, “Biotechnology” companies have a potential upside of 98.23%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Tonix Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
Tonix Pharmaceuticals Competitors	-12,359.35%	-203.09%	-30.93%

Valuation and Earnings

This table compares Tonix Pharmaceuticals and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11 million	-$124.02 million	-0.35
Tonix Pharmaceuticals Competitors	$698.09 million	$10.43 million	-15.42

Tonix Pharmaceuticals’ competitors have higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Tonix Pharmaceuticals beats its competitors on 8 of the 13 factors compared.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.